Popular on EntSun
- Rep. Gina H. Curry and Dr. Conan Tu Inspire at Kopp Foundation for Diabetes Hybrid Fundraising Gala and National Leadership Forum - 146
- Mullins McLeod Surges Into SC Governor's Race with $1.4 Million Raised in First Quarter; Most from His Own Commitment, Not Political Pockets - 139
- Hiclean Tools Releases HCX2100 Electric Pressure Washer - 126
- Jaipur's Savista Retreat announces $299 all-inclusive nightly rate for two for the 2026 season, including meals and city-center transfers - 120
- Eastman Craighead Periodontics Expands Professional Education and Collaboration for Dental Teams Across Southwest Florida - 113
- The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague - 112
- Wall Street's New Obsession? Tradewinds Aims to Revolutionize the $8B Gentlemen's Club Industry with National Peppermint Hippo™ Strategy $TRWD - 110
- Taraji P. Henson's Boris Lawrence Henson Foundation (BLHF) Announce 5th Annual Can We Talk? Arts & Wellness Summit and "i AM The Table Benefit Brunch - 110
- Root Canal Specialist In Frederick Maryland Joins Pearlfection Dentistry - 107
- NYC Public School Music Teacher & Singer-Songwriter Craig Klonowski Submits Five Songs for GRAMMY® Consideration - 104
Similar on EntSun
- Brazil 021 Chicago Launches New Website and Expands with No-Gi Classes for All Levels
- American Star Guard Unveils a Powerful Rebrand and Expanded Security Services Throughout Nevada
- Arnica Unveils "Arnie AI" to Secure the Future of AI-Driven Software Development
- Award-Winning Author Zane Carson Carruth Featured in USA Today for Inspiring Mission to Nurture Young Hearts Through Storytelling
- Parkchester Oral & Maxillofacial Surgery Celebrates 450+ 5-Star Reviews
- $430 Million 2026 Revenue Forecast; 26% Organic Growth; $500,000 Stock Dividend Highlight a Powerful AI & Digital Transformation Story: IQSTEL $IQST
- $73.6 Million Multi-Year Backlog and Florida State Term Contract Drive Momentum for AI-Cybersecurity Pioneer: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
- Year-Round Deals for Customers With Square Signs
- Peter Coe Verbica Stands with Rural Families and Horse Owners: "Keep Horses Classified as Livestock"
- Pastor Darrell Armstrong Suspends Gubernatorial Campaign And Endorses Mikie Sherrill
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe USA - English USA - English
EntSun News/10892356
RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants, finds Frost & Sullivan
SANTA CLARA, Calif., July 22, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global RNA Therapeutics: Technology Growth Opportunities, reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
For further information on this analysis, please visit: http://frost.ly/62g
"Advances in RNA stability, manufacturing, chemical modification, and targeted delivery systems have led to the commercial translation of RNA therapeutics," said Ruplekha Choudhurie, TechVision Industry Analyst at Frost & Sullivan. "RNAs are relatively easy to manufacture, cost-effective, and can act on undruggable targets. As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."
More on EntSun News
Choudhurie added: "RNAs have certain advantages over deoxyribonucleic acid (DNA) and small molecule drugs, such as eliminating the risk of genomic integration, being relatively cost-effective, and having rapid development and production. Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants. Specifically, for the development of vaccines for COVID-19 and other emerging infectious disease outbreaks, mRNA vaccines have an advantage over other types of vaccines as they can be rapidly developed and amenable to modifications to target evolving viral variants."
The advantages of RNA therapeutics over conventional small molecule drugs and other biological drugs present immense growth opportunities for market players, including:
Global RNA Therapeutics: Technology Growth Opportunities is the latest addition to Frost & Sullivan's TechVision research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.
More on EntSun News
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Global RNA Therapeutics: Technology Growth Opportunities
DA00
Contact:
Mariana Fernandez
Corporate Communications
E: [email protected]
http://ww2.frost.com
SOURCE Frost & Sullivan
Related Links
www.frost.com
SANTA CLARA, Calif., July 22, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global RNA Therapeutics: Technology Growth Opportunities, reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
For further information on this analysis, please visit: http://frost.ly/62g
"Advances in RNA stability, manufacturing, chemical modification, and targeted delivery systems have led to the commercial translation of RNA therapeutics," said Ruplekha Choudhurie, TechVision Industry Analyst at Frost & Sullivan. "RNAs are relatively easy to manufacture, cost-effective, and can act on undruggable targets. As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."
More on EntSun News
- American Star Guard Unveils a Powerful Rebrand and Expanded Security Services Throughout Nevada
- Queen Creek Xtreme Bulls 2025: Where Thanksgiving Weekend Meets Adrenaline
- PlaceBased Media Expands Point-of-Care Advertising Inventory Across U.S. Clinic Network
- Darkside, the Pink Floyd Show ends 20th anniversary tour at The Brierley Hill Civic Hall
- Nola Blue Records signs Curtis Salgado
Choudhurie added: "RNAs have certain advantages over deoxyribonucleic acid (DNA) and small molecule drugs, such as eliminating the risk of genomic integration, being relatively cost-effective, and having rapid development and production. Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants. Specifically, for the development of vaccines for COVID-19 and other emerging infectious disease outbreaks, mRNA vaccines have an advantage over other types of vaccines as they can be rapidly developed and amenable to modifications to target evolving viral variants."
The advantages of RNA therapeutics over conventional small molecule drugs and other biological drugs present immense growth opportunities for market players, including:
- Formulation and delivery of RNA therapeutics: Lipid-nanoparticles were used for delivery formulation in the previously approved RNA therapeutics, and similar (RNA-LNPs) formulations have been considered standard. Rapid formulation and delivery advances will improve the future of RNA delivery and help overcome the intrinsic stability issues of RNA.
- Stability of mRNA vaccines and RNA therapeutics at ambient temperature: Novel formulations that improve mRNA stability at ambient temperatures would facilitate the worldwide application of mRNA vaccines more rapidly and at a much lower cost. This will benefit mRNA vaccines and the entire RNA therapeutics field in general.
- mRNA vaccines and active participation of big pharmaceutical companies: Currently, RNA therapeutics is one of the fastest and most promising approaches in biological therapeutics. Due to this, many stakeholders are investing heavily in mRNA vaccines.
Global RNA Therapeutics: Technology Growth Opportunities is the latest addition to Frost & Sullivan's TechVision research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.
More on EntSun News
- Flexible Plan Investments launches FlexDirex, a first-to-market suite of single-stock ETF strategies in the U.S
- SUSTAINSEW Technologies Corp. Advances Key Platform Modules to Drive Sustainable Fashion Forward
- Culture, Classical Guitar and Comedy... HealthyLife.net Radio adds new programs
- Revenue Optics Ignites AI Revolution in Industrial Distribution
- Arnica Unveils "Arnie AI" to Secure the Future of AI-Driven Software Development
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Global RNA Therapeutics: Technology Growth Opportunities
DA00
Contact:
Mariana Fernandez
Corporate Communications
E: [email protected]
http://ww2.frost.com
SOURCE Frost & Sullivan
Related Links
www.frost.com
Filed Under: Business
0 Comments
Latest on EntSun News
- Divine Punk Announces Happy Christmas, a Holiday Soundscape by Rebecca Noelle
- $430 Million 2026 Revenue Forecast; 26% Organic Growth; $500,000 Stock Dividend Highlight a Powerful AI & Digital Transformation Story: IQSTEL $IQST
- Wzzph Deploys 5-Million-TPS Trading Engine with Hot-Cold Wallet Architecture Serving 500,000 Active Users Across Latin America
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Dominate Raleigh's Best Awards from The News & Observer
- $73.6 Million Multi-Year Backlog and Florida State Term Contract Drive Momentum for AI-Cybersecurity Pioneer: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
- Year-Round Deals for Customers With Square Signs
- GP Tha Boss Presents: Gang Gang LA
- SecurePII Raises US$3.5M (A$5M) to Unlock AI and Compliance for Voice Data and Expands Global Presence
- Famous Comedian and Magician Andy Gross Inducted into the Missouri Raquetball Hall of Fame
- Peter Coe Verbica Stands with Rural Families and Horse Owners: "Keep Horses Classified as Livestock"
- The Moms Dance Party™ Hits Salt Lake City With the Ultimate Self-Care Night Out
- The Mobile-First Company Raises $12M to Build Simple, Powerful Software for Small Teams
- Lick Pineapple Flavored Massage Oil Outperforming and Enticing
- For Election Day: Treat yourself to a funny poem and a song about politics called "Run For Office"
- Colter, Holloway, Frakes, Lewis, Wright Among Additions to FAN EXPO Portland Lineup
- Cerberus ODC in Collaboration with NVIDIA Launches All-American AI-RAN Stack, Enabling AI-Native 5G Today and Accelerating the Path to 6G
- National Compliance Firm issues Artificial Intelligence Policy Program for Mortgage Banking
- Malibu Jack's Indoor Theme Park will open on November 3rd in Thornton, CO at Thornton Towne Center
- Pastor Darrell Armstrong Suspends Gubernatorial Campaign And Endorses Mikie Sherrill
- Dr. Johnny Shanks Attends Full Arch Growth Conference 2025
